

# Chronic Renal Insufficiency

## *A Diagnostic and Therapeutic Approach*

Mahboob Rahman, MD; Michael C. Smith, MD

**C**hronic renal insufficiency ultimately culminating in end-stage renal disease requiring dialysis or transplantation is a major health problem in the United States. The first task confronting the physician caring for a patient with renal disease is to decide whether the renal insufficiency is acute or chronic. The initial differential diagnostic approach to chronic renal insufficiency consists of determining whether the patient has glomerular disease or interstitial or vascular disease on the basis of a careful history taking, urinalysis, and measurement of 24-hour protein excretion. Further refinement of diagnostic considerations often requires serologic studies, renal biopsy, or imaging the urinary tract with ultrasonography or computed tomography. Management considerations begin with the identification and correction of any acute reversible causes of renal insufficiency in patients with chronic renal disease. Recent studies have shown that effective antihypertensive therapy, especially with angiotensin-converting enzyme inhibitors, restriction of dietary protein, and excellent glycemic control in patients with diabetes, can retard the progression of chronic renal disease. Once these therapeutic strategies are in place, it is important to anticipate and treat the multiple manifestations of chronic progressive renal insufficiency: fluid overload, hyperkalemia, metabolic acidosis, abnormalities of calcium, phosphorus, and vitamin D metabolism, and anemia. *Arch Intern Med.* 1998;158:1743-1752

Chronic renal failure (CRF) is a significant cause of morbidity and mortality in the United States. Currently more than 170 000 patients receive maintenance dialysis and approximately 60 000 patients have functioning kidney transplants.<sup>1</sup> The incidence of end-stage renal disease (ESRD) has increased steadily over the last decade; in 1993, the adjusted incidence rate of treated ESRD was 210 per million population per year, yielding a growth rate of 7.5% per year since 1984.<sup>1</sup> Treatment for ESRD costs approximately \$9.5 billion per year and represents a significant financial burden to the health care system.<sup>1</sup> Diabetes, hypertension, and chronic

glomerulonephritis are the most common causes of ESRD responsible for 37%, 30%, and 12%, respectively, of incident cases of ESRD. Cystic kidney diseases, interstitial nephritis, obstructive nephropathy, and other causes account for the remaining cases of ESRD.<sup>1</sup>

Optimal management of patients with chronic renal insufficiency requires initial nephrologic consultation. However, prior to the development of ESRD, many patients with mild to moderate renal insufficiency receive the majority of their medical care from primary care physicians rather than nephrologists. Thus, a sound understanding of the pathophysiological features and clinical manifestations of CRF is essential to treat patients with declining renal function. This review summarizes key concepts in the di-

*From the Department of Medicine, Case Western Reserve University School of Medicine, and the Divisions of Hypertension and Nephrology, University Hospitals of Cleveland, Cleveland, Ohio.*

**Table 1. Diagnostic Approach to Chronic Renal Insufficiency**

Glomerular Disease	Interstitial or Vascular Disease
Diagnostic features: red blood cell casts, >3.5 g of protein excretion, or systemic disease associated with a glomerulopathy	Diagnostic features: bland urinalysis, <2-3 g of protein excretion, no systemic disease associated with a glomerulopathy
Primary	Anatomical abnormalities
Focal glomerulosclerosis	Obstructive nephropathy
Membranous nephropathy	Polycystic kidney disease
Membranoproliferative glomerulonephritis	Hypertensive nephrosclerosis
Secondary	Analgesic abuse
Diabetic nephropathy	Nephrolithiasis
Lupus nephritis	Idiopathic
Amyloidosis	Ischemic nephropathy

agnosis and treatment of pre-end-stage chronic renal insufficiency and provides practical guidelines for management.

### MEASUREMENT OF RENAL FUNCTION

Measurement of glomerular filtration rate (GFR) either by inulin or iodine I 125-iodothalamate clearance has been the criterion standard for estimation of renal function.<sup>2</sup> However, these techniques are cumbersome to perform on a routine basis and, hence, limited to research protocols. In clinical practice, determinations of serum creatinine, creatinine clearance, and the reciprocal of the serum creatinine are commonly used for diagnosis of renal dysfunction and monitoring progression of renal disease. Factors other than GFR, including generation, tubular secretion, and extrarenal elimination of creatinine, affect serum creatinine concentration. Therefore, these determinations may not always be accurate estimates of renal function, especially in patients with mild renal insufficiency.<sup>3</sup> While the slope of the reciprocal of serum creatinine vs time has been advocated to monitor the rate of progression of chronic renal disease,<sup>4</sup> the occurrence of spontaneous break points in the slope, with improvement, stabilization, or accelerated decline in renal function, limits the use of this technique.<sup>5</sup> Furthermore, drugs such as trimethoprim and cimetidine inhibit tubular secretion of creatinine and can increase serum creatinine levels,<sup>6,7</sup> especially in patients with moderate to severe renal dysfunction.<sup>8</sup>

Consequently, although measurement of serum creatinine and creatinine clearance are the only practical clinical methods to follow renal function, the potential limitations of these techniques should be recognized.

### ACUTE VS CHRONIC RENAL FAILURE

The initial diagnostic challenge in evaluating a patient with an elevated serum creatinine level is to determine whether the renal dysfunction is acute or chronic. In most cases, previous serum creatinine measurements will clarify the issue. Under some circumstances, however, these data are not available and the physician must depend on clinical evaluation, laboratory studies, and radiological features to make this important distinction.

Patients with acute renal insufficiency usually have a readily identifiable precipitating event such as volume depletion, urinary tract obstruction, or the administration of potentially nephrotoxic drugs (eg, nonsteroidal anti-inflammatory drugs [NSAIDs] or angiotensin-converting enzyme [ACE] inhibitors) temporally related to the increment in serum creatinine level. Moreover, individuals with acute renal insufficiency tend to be more symptomatic at any given level of renal dysfunction compared with patients with CRF. Moderate to severe anemia, hypocalcemia, and hyperphosphatemia are frequent accompaniments of CRF whereas these hematologic and biochemical abnormalities are less marked in acute

renal failure. Ultrasonographic determination of renal size is helpful in distinguishing acute from chronic renal insufficiency; while renal size can be normal in both acute and chronic renal disease, the presence of bilaterally small kidneys is diagnostic of chronic irreversible renal insufficiency.<sup>9</sup> Hence, a combination of previous measurements of renal function, careful clinical evaluation, and selected laboratory and radiological studies generally permit the physician to establish the diagnosis of chronic renal disease with confidence.

### ETIOLOGY OF CRF

From an etiologic perspective, chronic renal insufficiency can be broadly divided into glomerular disease and interstitial or vascular disease (**Table 1**). This distinction is usually made on the basis of several laboratory and clinical features. The presence of red blood cell casts on urinalysis, proteinuria of more than 3.5 g/24 h, or a systemic disease strongly associated with a glomerulopathy (eg, diabetes or lupus erythematosus) is highly suggestive of underlying glomerular disease.<sup>9</sup> In contrast, patients who lack a systemic illness associated with a glomerulopathy have bland urinalysis findings and exhibit protein excretion of less than 2 to 3 g/24 h are likely to have interstitial disease<sup>9</sup> or ischemic nephropathy.

Definitive diagnosis of nondiabetic glomerular disease usually requires a kidney biopsy. Although a variety of serologic studies (eg, complement levels or antinuclear antibody) can be obtained, they usually do not circumvent the need for a biopsy if a precise diagnosis is required. On the other hand, a reliable clinical diagnosis of diabetic nephropathy can be made in the presence of the proper duration of diabetes (7-8 years in type 2 diabetes mellitus or 12-15 years in type 1 diabetes mellitus), coexistent diabetic retinopathy, and nephrotic range proteinuria.<sup>10-12</sup> Chronic interstitial nephritis, however, can have similar histological findings regardless of cause.<sup>9</sup> Therefore, establishing a specific diagnosis in patients with chronic interstitial nephritis requires knowl-

edge of the common diseases associated with chronic interstitial injury (Table 1), relevant historical data, and renal imaging studies. A careful history of analgesic ingestion should be obtained to exclude the possibility of analgesic nephropathy.<sup>13</sup> Hypertensive nephrosclerosis is a common cause of chronic interstitial nephritis, particularly in African Americans. The diagnosis is likely in the presence of a long history of hypertension, especially if blood pressure has been poorly controlled, in association with nonnephrotic-range proteinuria.<sup>14-17</sup> Obstructive nephropathy, polycystic kidney disease, and stone disease can be excluded by ultrasonography or computed tomography. Ischemic renal disease should be suspected in patients with a significant history of cigarette smoking who demonstrate clinical evidence of extrarenal vascular disease<sup>18</sup> and have asymmetrical kidneys on renal ultrasonography.

#### MANAGEMENT OF CRF

The management of patients with chronic renal insufficiency has several components. First, the physician must identify and correct reversible causes of acute decrements in GFR superimposed on chronic renal disease. Second, in the absence of specific therapeutic maneuvers to stabilize or improve renal function, non-specific measures should be used to ameliorate the progression of renal disease. Third, the multiple clinical manifestations of progressive renal insufficiency should be recognized and treated. Finally, as renal failure progresses, patient education and planning regarding initiation of renal replacement therapy should be done well in advance to ensure a smooth transition to ESRD.

#### IDENTIFICATION AND TREATMENT OF REVERSIBLE DECREASES IN RENAL FUNCTION

Patients with chronic renal insufficiency of any cause are prone to develop further acute decrements in renal function under a variety of circumstances. Disturbed autoregulation of renal blood flow (RBF) and increased sensitivity to the nephro-

toxic effects of various pharmacological agents account for this enhanced susceptibility. Factors most frequently responsible for acute declines in renal function in patients with CRF are volume depletion; congestive heart failure; urinary tract obstruction; accelerated hypertension; nephrotoxic drugs (eg, aminoglycoside antibiotics or NSAIDs); radiocontrast media; and ischemic nephropathy.

#### Volume Depletion

The normal kidney maintains a relatively constant RBF and GFR across a broad range of mean arterial pressure (80-180 mm Hg) by modulation of afferent arteriolar tone. However, in the presence of diabetes, hypertension, or reduced renal mass, autoregulation of RBF is impaired.<sup>19-21</sup> Consequently, if systemic blood pressure decreases, the afferent arteriole cannot dilate appropriately, leading to an acute decline in GFR. In addition, patients with chronic renal disease have limited ability to abruptly curtail sodium excretion in the face of extrarenal volume depletion, thus potentially exacerbating the salt loss.<sup>22</sup>

Volume deficits are often precipitated by gastrointestinal losses (eg, vomiting or diarrhea), excessive dietary sodium restriction, or overzealous diuretic administration. In severe cases, volume-depleted patients manifest weight loss, orthostatic changes in pulse and blood pressure, dry mucous membranes, and poor skin turgor. Under these circumstances, prompt identification of the source of volume depletion and correction of volume deficits generally stabilizes and improves renal function. Not infrequently, however, the diagnosis is more challenging and the clinical evidence of volume depletion is subtler. Under the latter circumstances, a cautious trial of volume repletion (eg, reducing the dose of diuretics or increasing dietary sodium) often establishes the diagnosis and restores renal function to baseline.

#### Congestive Heart Failure

The low cardiac output in patients with congestive heart failure reduces RBF and GFR.<sup>23</sup> In addition, activation of several neurohumoral

systems, including the renin angiotensin axis and the sympathetic nervous system,<sup>24</sup> causes intrarenal vasoconstriction further decreasing renal function. In the setting of an already limited ability to excrete salt and water, this additional constraint on sodium excretion can precipitate volume overload and pulmonary edema.

Since thiazide diuretics are usually ineffective at creatinine clearances less than 0.50 mL/s,<sup>25</sup> loop diuretics are the mainstay of management of patients with congestive heart failure and chronic renal insufficiency. Chronic administration of loop diuretics to patients with congestive heart failure decreases afterload and increases cardiac output.<sup>26</sup> Although ACE inhibitors reduce morbidity and mortality in patients with congestive heart failure and normal renal function, their routine application in patients with renal insufficiency and impaired systolic function should be considered carefully. As renal function declines, the beneficial hemodynamic and clinical effects of ACE inhibition are progressively attenuated.<sup>27</sup> Furthermore, ACE inhibitors can cause acute decreases in GFR in patients with chronic renal insufficiency.<sup>28</sup> Hence, if ACE inhibitors are used to treat systolic dysfunction in patients with underlying renal disease, the patients should be closely monitored for hypotension, worsening renal function, and hyperkalemia. Digitalis glycosides usually are not required; they are of marginal therapeutic benefit in this patient population and can impair extrarenal potassium homeostasis.<sup>29,30</sup>

#### Urinary Tract Obstruction

The most common cause of obstructive nephropathy, particularly in elderly men, is prostatic hypertrophy. Other causes include renal papillary necrosis, stones, pelvic malignancy, retroperitoneal fibrosis, or neurogenic bladder.<sup>31</sup> The effects of urinary tract obstruction on renal function are diverse and include marked reduction in RBF and GFR and significant defects in tubular reabsorption of water and solute.<sup>32</sup> Ultrasonographic evaluation is the diagnostic modality of choice<sup>33</sup> and prompt uro-

logic consultation should be sought if obstruction is detected.

### Accelerated Hypertension

Malignant hypertension generally presents with severe elevations in diastolic pressure (usually >140 mm Hg) associated with evidence of vascular damage as manifested by retinal hemorrhages, exudates, or papilledema. Renal parenchymal disease is the most common cause of malignant hypertension<sup>34</sup> and a further acute chronic decline in renal function can occur because of myointimal proliferation and fibrinoid necrosis of the renal vascular bed.<sup>34</sup> Although reduction of blood pressure in these circumstances often causes a further transient decline in renal function attributable to impaired autoregulation of RBF,<sup>19,21</sup> continued good blood pressure control can improve renal function in the long-term.<sup>35</sup> In fact, some patients who require dialytic support have been able to discontinue dialysis with adequate blood pressure control.<sup>36</sup> The initial goal of therapy should be to decrease blood pressure to 160 to 170/100 mm Hg over 24 to 48 hours with a subsequent reduction to normotensive levels over days to weeks.

### Drugs

Patients with chronic renal insufficiency are at increased risk compared with subjects with normal renal function to develop drug-induced acute renal dysfunction. In this regard, aminoglycosides are an important cause of acute on chronic renal insufficiency. Aminoglycoside nephrotoxicity typically presents as nonoliguric acute renal failure 7 to 10 days after initiation of therapy. Risk factors for aminoglycoside nephrotoxicity include advanced age, prolonged duration of therapy, frequent dosing intervals, greater total aminoglycoside dose, liver disease, the presence of hypotension, hypovolemia, or shock, and chronic renal insufficiency.<sup>37-39</sup> Although a once-daily regimen may be less nephrotoxic than multiple daily doses in patients with normal renal function,<sup>40</sup> similar data are not available in patients with chronic renal

insufficiency. Hence, aminoglycoside therapy should be administered cautiously to patients with chronic renal insufficiency, and renal function and serum drug levels should be monitored frequently.

Nonsteroidal anti-inflammatory drugs have been associated with multiple renal complications including acute reversible vasomotor renal failure, hyperkalemia, salt and water retention, acute interstitial nephritis and nephrotic syndrome, and interstitial nephritis with varying degrees of renal insufficiency.<sup>41</sup> Acute vasomotor renal failure precipitated by NSAIDs usually occurs in the presence of chronic renal insufficiency, concomitant diuretic therapy, volume depletion, congestive heart failure, cirrhosis, nephrotic syndrome, or advanced age.<sup>41,42</sup> Most of these pathophysiological circumstances are associated with increased production of vasoconstrictor compounds including angiotensin II, catecholamines, and vasopressin. These hormones not only decrease RBF and GFR but also simultaneously increase the synthesis of vasodilator prostaglandins in the kidney that attenuate the vasoconstrictor-induced reduction in RBF and GFR.<sup>43</sup> Administration of NSAIDs inhibits the synthesis of vasodilator prostaglandins and, hence, results in unopposed intrarenal vasoconstriction with a consequent decline in GFR. Some reports<sup>44,45</sup> suggest that sulindac and piroxicam may be less nephrotoxic than other agents. Nevertheless, the use of NSAIDs should be avoided if possible, or minimized in patients with chronic renal insufficiency. If NSAIDs are required in patients with CRF, renal function should be carefully monitored.

### Contrast Media

Radiopaque contrast agents are a frequent cause of nephrotoxic effects in patients with chronic renal insufficiency. Diabetes, preexisting renal insufficiency, and the volume of contrast administered are the major risk factors for development of contrast nephropathy.<sup>46-48</sup> Contrast media-induced acute renal failure generally occurs within 24 to 48 hours of the dye administration.<sup>49</sup> The

clinical course is typical with peak serum creatinine concentration developing after 5 to 7 days and usually returning to baseline in 10 to 14 days.<sup>49</sup> However, a significant proportion of patients with a baseline serum creatinine concentration higher than 442  $\mu\text{mol/L}$  (5 mg/dL) may require temporary or permanent dialysis.<sup>48,50</sup> Hydration with 0.45% normal saline solution before, during, and after the procedure, and use of non-ionic contrast media in patients with preexisting renal dysfunction, especially diabetic nephropathy,<sup>51</sup> can minimize the risk of radiocontrast nephropathy.<sup>52</sup>

### Ischemic Renal Disease

Ischemic renal disease, defined as a clinically significant reduction in GFR in patients with hemodynamically significant obstruction to RBF,<sup>53</sup> is a more common cause of renal dysfunction than previously estimated.<sup>18,54</sup> Clinical features indicative of ischemic renal disease include significant increments in serum creatinine associated with antihypertensive therapy, especially ACE inhibitors,<sup>55</sup> progressive azotemia in patients with refractory hypertension, and unexplained renal dysfunction in elderly patients with extrarenal vascular disease.<sup>53</sup> Recurrent pulmonary edema, poorly controlled hypertension, and renal insufficiency comprise a characteristic triad suggestive of ischemic renal disease.<sup>56,57</sup> Ischemic nephropathy frequently progresses,<sup>58-60</sup> often to total bilateral renal artery occlusion, and may account for 5% to 15% of all patients developing ESRD.<sup>18,54</sup> Revascularization by angioplasty or surgery can improve renal function, control blood pressure, and eliminate recurrent episodes of pulmonary edema.<sup>56,57,61,62</sup>

### SLOWING THE PROGRESSION OF RENAL DISEASE

In most forms of chronic renal insufficiency, once GFR is reduced to 0.42 to 0.5 mL/s, renal function declines inexorably regardless of the primary insult.<sup>63,64</sup> While multiple factors such as intraglomerular coagulation, abnormal calcium and

phosphorus metabolism, and hyperlipidemia have been implicated in the progression of experimental renal disease,<sup>64</sup> their clinical relevance remains to be established. On the other hand, systemic hypertension,<sup>65,66</sup> dietary protein intake,<sup>67</sup> and glycemic control in patients with diabetes<sup>68</sup> play significant roles in the progression of human renal disease. A National Institutes of Health workshop group<sup>69</sup> has recently summarized recommendations for prevention of progression in chronic renal disease.

### Control of Blood Pressure

Hypertension is an important manifestation of chronic renal disease and increases in prevalence as renal function declines.<sup>70</sup> Systemic hypertension can have a deleterious effect on renal function in 2 ways. First, it may be the primary factor initiating renal dysfunction in patients with hypertensive nephrosclerosis.<sup>14</sup> Second, poorly controlled blood pressure accelerates progression of both diabetic and nondiabetic renal disease.<sup>70,71</sup> The adverse effect of elevated blood pressure on renal function may be mediated by increased intraglomerular pressure<sup>63,72</sup> or glomerular hypertrophy<sup>73</sup> or both, leading to progressive glomerular sclerosis and renal dysfunction.

The beneficial effects of blood pressure reduction to decrease cardiovascular morbidity and mortality are well established. In addition, numerous prospective trials<sup>74-76</sup> have shown that excellent blood pressure control can ameliorate the progression of renal disease. The available data indicate that control of hypertension to 130/80 to 85 mm Hg should be a minimum goal in patients with chronic renal insufficiency.<sup>69</sup> Furthermore, a secondary analysis of the recently concluded Modification of Diet in Renal Disease Study<sup>75</sup> suggests that patients with proteinuria (>1 g/24 h) may benefit from reduction of blood pressure to a goal of less than 125/75 mm Hg. Several classes of drugs can be used to control blood pressure in patients with chronic renal insufficiency. Due to their ability to inhibit the proliferative and intra-

renal hemodynamic effects of angiotensin II, ACE inhibitors are generally considered to be more renoprotective than other antihypertensive agents.<sup>69</sup> However, the ongoing African American Study of Kidney Disease and Hypertension<sup>77</sup> should provide comparative data about several different classes of antihypertensive agents with regard to preservation of renal function in hypertensive renal disease.

### Restriction of Dietary Protein

In experimental renal disease, dietary protein restriction decreases intraglomerular pressure and retards the decline of renal function.<sup>78,79</sup> Clinical trials of protein restriction in humans, however, have yielded variable results. Some studies<sup>80,81</sup> have shown no benefit with regard to the rate of loss of renal function, while others<sup>82-84</sup> have found that progression of renal disease is ameliorated by a low-protein diet. The Modification of Diet in Renal Disease Study<sup>85</sup> was the largest prospective trial examining this issue, but after a mean follow-up of 2.2 years it was not able to show a statistically significant benefit of a low-protein diet (0.58 g/kg per day) or a very low-protein diet (0.28 g/kg per day), supplemented with keto acids, compared with a usual-protein diet (1.3 g/kg per day) in retarding the progression of renal disease. However, after an initial decline in GFR that may have been hemodynamically mediated, the low-protein group demonstrated a slower decline in renal function compared with the usual-protein group. No significant adverse effects of protein restriction were noted.

In patients with moderate loss of renal function (GFR, 25-55 mL/min per 1.73 m<sup>2</sup>), the National Institutes of Health workshop group<sup>69</sup> recommends a standard protein intake (>0.8 g/kg per day). If there is evidence of progression of renal insufficiency or development of uremic symptoms, an intake of 0.8 g of protein per kilogram per day may be appropriate. For patients with more severe renal dysfunction (GFR, 13-25 mL/min per 1.73 m<sup>2</sup>), a diet containing 0.6 g of protein per ki-

logram per day is recommended. Hence, dietary protein restriction can be an important therapeutic modality to slow the progression of renal disease, especially in normotensive patients with nondiabetic renal disease. However, because some patients with chronic progressive renal insufficiency spontaneously reduce dietary protein intake and develop other indexes of malnutrition,<sup>86</sup> implementation of such a diet should be done under the auspices of a renal dietician and with a dequate long-term nutritional counseling.

### Control of Blood Glucose

Diabetic nephropathy develops in 30% to 40% of patients with type 1 diabetes mellitus and 10% to 20% of patients with type 2 diabetes mellitus.<sup>87-89</sup> A genetic predisposition to hypertension,<sup>90,91</sup> poor glycemic control,<sup>90</sup> and an increased GFR<sup>92</sup> are risk factors for the development of diabetic nephropathy. Microalbuminuria (30-300 mg/d or 20-200 µg/min) is a good marker of early nephropathy and identifies patients at high risk for development of other microvascular and macrovascular complications.<sup>93</sup> Therefore, patients with type 1 diabetes mellitus for more than 5 to 10 years and/or a family history of renal disease or hypertension should be screened annually for microalbuminuria.<sup>69</sup> Recent studies<sup>68,94</sup> have confirmed that excellent control of blood glucose in type 1 diabetes mellitus (preprandial glucose, 3.8-6.6 mmol/L [70-120 mg/dL]; hemoglobin A<sub>1c</sub>, <0.07) prevents or delays development of long-term complications. Consequently, the goal should be to maintain the blood glucose within or close to normal range while minimizing hypoglycemic attacks.<sup>69</sup> Because ACE inhibitors have been shown to delay progression of renal disease in type 1 diabetes mellitus compared with conventional antihypertensive therapy (exclusive of calcium channel blockers),<sup>95,96</sup> they are the preferred antihypertensive drugs in hypertensive patients with diabetes, especially those with persistent microalbuminuria or overt proteinuria.<sup>69,97</sup> Despite the fact that most

**Table 2. Clinical Manifestations of Chronic Renal Insufficiency**

Cardiovascular	Hematologic
Fluid overload	Anemia
Hypertension	Platelet dysfunction
Electrolyte and acid-base levels	Neurologic
Hyperkalemia	Peripheral neuropathy
Metabolic acidosis	Encephalopathy
Endocrine	Rheumatologic
Calcium, phosphorus, vitamin D abnormalities	Crystal-induced arthritis
Gonadal dysfunction	Amyloid deposition

of the data and recommendations in the literature relate to type 1 diabetes mellitus, it is reasonable for the clinician to plan a similar regimen of good glycemic and blood pressure control, along with ACE inhibition, in patients with type 2 diabetes mellitus provided no contraindications exist.<sup>69</sup>

#### MANIFESTATIONS AND TREATMENT OF CRF

Chronic progressive renal insufficiency results in multiple clinical manifestations involving several organ systems. Some of the more prominent features are shown in **Table 2**. As renal function decreases, the clinical manifestations increase in severity and prevalence. Whereas fluid overload and hypertension can occur with mild renal dysfunction, hyperkalemia, abnormalities of calcium and phosphorus metabolism, acidosis, and anemia develop with moderate to severe renal failure. All of these consequences occur in patients with ESRD.

##### Fluid Overload

The ability of patients with CRF to excrete salt and water is limited not only because of a decrease in GFR but also because of the activation of various salt-retaining neurohumoral stimuli (eg, angiotensin II, aldosterone, and the sympathetic nervous system).<sup>70</sup> Hence, as renal insufficiency advances, dietary intake of sodium should be restricted to 80 to 90 mmol/d particularly if patients are hypertensive. Diuretic therapy eventually is necessary in most patients with progressive renal dysfunction to maintain salt and water balance. In patients with a GFR of less than 0.42 to 0.33 mL/s,

thiazide diuretics are generally ineffective<sup>25,98</sup> and high doses of loop diuretics in a twice-daily regimen are required to achieve adequate natriuresis. However, administration of thiazides in addition to loop diuretics can result in a marked natriuresis even in patients with advanced renal failure.<sup>99</sup> In patients resistant to high doses of oral diuretics or in those requiring acute diuresis, parenteral administration is often necessary. In this regard, a continuous infusion of a loop-blocking diuretic is more effective than administration of repeated boluses.<sup>100</sup>

##### Hypertension

Abnormal salt metabolism is a central factor in the development of hypertension in patients with CRF. In addition, other vasoconstrictor stimuli (eg, angiotensin II or sympathetic nervous system) that also limit sodium excretion play important roles in the development and maintenance of high blood pressure in these patients.<sup>101</sup> Hence, salt restriction and diuretic therapy are essential for adequate control of blood pressure and form the cornerstone of treatment. Most patients, however, require additional antihypertensive drug therapy. Although multiple classes of antihypertensive agents are available, we prefer calcium channel blockers, ACE inhibitors, and centrally acting sympatholytics because they are effective and rational from a pathophysiological perspective. Calcium channel blockers and ACE inhibitors reduce blood pressure in patients with renal insufficiency and probably exert a beneficial renoprotective effect.<sup>74,102-105</sup> In addition, calcium channel blockers are also effective at extremes of dietary salt

intake.<sup>105</sup> Finally, centrally acting agents such as clonidine inhibit the central sympathetic outflow that is increased in hypertensive patients with chronic renal disease<sup>106</sup> and are effective antihypertensive agents. Whichever antihypertensive regimen is selected, reduction of blood pressure to 130/80 to 85 mm Hg should be the goal.

Accumulating data indicate that both ACE inhibitors and calcium channel antagonists slow the rate of progression of renal disease to a greater extent compared with other classes of antihypertensive agents.<sup>74,95,102-105,107-117</sup> In patients with diabetic nephropathy, multiple studies have demonstrated that ACE inhibition reduces proteinuria<sup>96,117,118</sup> and retards the progression of renal disease<sup>95,97,107,119,120</sup> compared with noncalcium channel blocker-based conventional antihypertensive therapy. While no large-scale trials comparing the renoprotective effects of ACE inhibition with calcium channel blockade in diabetic nephropathy have been published, 2 recent small studies have shown similar effects of both classes of drugs with regard to urinary albumin excretion and GFR after 1<sup>112</sup> and 3<sup>113</sup> years of treatment. In nondiabetic kidney disease, similar data are emerging. A recent meta-analysis of randomized trials<sup>107</sup> found that 5 of 8 studies comparing ACE inhibition with noncalcium channel blocker antihypertensive therapy demonstrated slower progression of renal disease in the group that received ACE inhibitors. A recent Italian multicenter trial<sup>116</sup> confirmed these findings. However, the 2 long-term prospective studies<sup>74,107</sup> comparing ACE inhibition with calcium channel blockade found that both retarded the decline in renal function to a similar extent. Taken together, these observations indicate that both classes of drugs are similarly effective in ameliorating the progression of renal disease and that therapy with either is superior to alternative antihypertensive regimens in slowing the decline in renal function. Whether this beneficial effect is the result of greater antihypertensive efficacy<sup>74,107,111</sup> or intrinsic renoprotective properties<sup>109,110</sup> remains to be determined.

## Hyperkalemia

Although most patients with chronic renal insufficiency can maintain potassium homeostasis until creatinine clearance is 0.25 to 0.33 mL/s,<sup>121</sup> several factors (**Table 3**) predispose to the development of hyperkalemia with lesser degrees of renal dysfunction. Multiple drugs such as ACE inhibitors, NSAIDs, potassium-sparing diuretics, nonselective  $\beta$ -blockers, and digitalis can precipitate hyperkalemia in patients with underlying renal insufficiency.<sup>122</sup> Patients with diabetic nephropathy are especially prone to develop hyperkalemia because of type IV renal tubular acidosis and because of impaired cellular potassium uptake consequent to insulin deficiency.<sup>123</sup> Dietary intake of potassium should be limited to 60 mmol/d to minimize the development of hyperkalemia, and salt substitutes should be avoided. Occasionally, treatment with sodium-potassium exchange resins such as sodium polystyrene sulfonate is required to control hyperkalemia as patients approach ESRD.

### Calcium, Phosphorus, and Vitamin D Abnormalities

Renal osteodystrophy is frequently seen in CRF and is characterized by varying amounts of osteitis fibrosa cystica, osteomalacia, and adynamic bone disease.<sup>124</sup> Hyperphosphatemia due to the decrease in GFR and reduced renal synthesis of 1,25-dihydroxy D<sub>3</sub> results in low serum calcium levels and secondary hyperparathyroidism.<sup>125</sup> Elevated parathyroid hormone concentrations cause mobilization of calcium from bone eventually leading to osteitis fibrosa cystica. Complex interactions of hyperparathyroidism, 1,25-dihydroxy D<sub>3</sub> deficiency, aluminum intoxication, local cytokines,  $\beta_2$ -microglobulin, and associated gonadal dysfunction ultimately determine the development of 1 of the above 3 lesions.<sup>124</sup> Although a bone biopsy is required to make a definitive histological diagnosis, most clinicians rely on serum concentrations of calcium, phosphorus, parathyroid hormone, aluminum, and alkaline phosphatase to guide therapy.

The goals of management of renal osteodystrophy should be to

maintain calcium and phosphorus levels within normal limits and parathyroid hormone at 2 to 3 times the upper limit of normal. In addition to a low-phosphate diet, a calcium-based phosphate binder (calcium acetate or carbonate) is usually required. The starting dose of calcium carbonate of 0.5 g with each meal can be increased until the serum phosphorus concentration is normalized; patients generally require between 5 and 10 g/d.<sup>126</sup> Aluminum-containing phosphate binders should be avoided to limit the risk of aluminum toxicity (osteomalacia, anemia, or encephalopathy), but may be necessary on a temporary basis if the calcium phosphorus product is more than 65 to 70 (when calcium and phosphorus are expressed in milligrams per deciliter, or approximately 6 when measured in SI units) to minimize the potential for extraskel-etal calcification. Oral calcitriol (0.125-0.25  $\mu$ g/d) is effective in increasing serum calcium concentration, reducing parathyroid hormone levels, and improving renal osteodystrophy.<sup>127,128</sup> However, serum calcium levels should be monitored periodically in patients receiving calcitriol to prevent the development of hypercalcemia.

### Metabolic Acidosis

Chronic renal insufficiency is associated with a progressive inability to excrete normal endogenously produced nonvolatile acid and usually results in systemic acidosis when the GFR is reduced to 0.42 mL/s or less.<sup>129</sup> Impaired renal ammonia production and reduced bicarbonate reabsorption are the major factors responsible for the development of the metabolic acidosis.<sup>130,131</sup> Since bone buffering of the chronic acidosis may contribute to the development of renal osteodystrophy,<sup>126</sup> treatment with supplemental alkali (either as sodium bicarbonate or Shohl solution) at a dosage of 20 mmol of bicarbonate twice daily should be initiated and titrated upward to achieve a serum bicarbonate concentration of 22 to 24 mmol/L.<sup>126</sup>

### Anemia

Most patients with chronic renal insufficiency develop a normocytic, normochromic, hypoproliferative

**Table 3. Renal and Extrarenal Factors That Predispose to Hyperkalemia**

Increased intake
Diet
Salt substitutes
Redistribution from intracellular to extracellular fluid or reduced cell uptake
Insulin deficiency
Acidosis
Nonselective $\beta$ -blockade
Digitalis
Decreased renal potassium excretion
Potassium-sparing diuretics
Trimethoprim
Hypoadosteronism
Idiopathic
Type IV renal tubular acidosis
Drug induced
Angiotensin-converting enzyme inhibitors
Nonsteroidal anti-inflammatory drugs
Heparin

anemia.<sup>132</sup> Decreased erythropoietin production is the principal factor responsible for the anemia of CRF<sup>133</sup>; however, shortened red blood cell survival,<sup>134</sup> associated iron and folate deficiencies, and "uremic" inhibition of erythropoiesis also contribute to the decrease in red blood cell mass.<sup>132</sup> The reduction in red blood cell mass results in multiple clinical manifestations, including fatigue, dyspnea, anorexia, nausea, and depression. Recombinant human erythropoietin has been a landmark in the treatment of the anemia of chronic renal disease. Weekly subcutaneous administration of erythropoietin at a mean dose of 150 U/kg increases the hematocrit to more than 0.3 in predialysis patients with CRF<sup>135-137</sup> and an average weekly dose of 75 U/kg is an effective maintenance dose once goal hematocrit has been reached. Amelioration of the anemia of CRF with erythropoietin not only improves symptoms but also exerts beneficial effects on the hyperdynamic circulatory state associated with the anemia<sup>138</sup> and improves quality-of-life measures.<sup>139</sup> However, erythropoietin can cause an increase in blood pressure, and patients should be closely monitored for the need of additional antihypertensive therapy.<sup>140</sup>

### DRUG THERAPY

The physiological changes associated with renal insufficiency exert

important effects on the pharmacology of many frequently used drugs. Decreased renal function can affect absorption, distribution, metabolism, and elimination of many pharmacological agents. Several excellent resources, including the *Physicians' Desk Reference*, can be consulted to guide drug dosing in the presence of renal insufficiency.<sup>141,142</sup>

## DIET

Dietary modification in chronic renal insufficiency is complex and best accomplished in coordination with a registered dietitian. Since a low serum albumin concentration is a strong independent predictor of mortality in patients undergoing dialysis,<sup>143</sup> every effort should be made to maintain adequate nutritional balance in patients with CRF. Restriction of sodium intake to approximately 100 mmol/d is indicated in patients with hypertension and fluid overload. Modification of protein intake in chronic renal disease was discussed in detail earlier. Limiting daily phosphate intake to 600 to 800 mg/d is important in the management of renal osteodystrophy,<sup>144</sup> and daily potassium intake should be less than 60 mmol/d. This diet should provide 147 to 168 kJ/kg per day in energy intake, chiefly from carbohydrate and polyunsaturated fats.<sup>145</sup>

## TREATMENT MODALITIES IN ESRD

Hemodialysis, peritoneal dialysis, and kidney transplantation are the 3 major treatment modalities in patients with ESRD.<sup>1</sup> In patients without diabetes, access for dialysis is usually constructed when the creatinine clearance reaches 0.16 mL/s, whereas in patients with diabetes, access is generally established at a creatinine clearance of 0.16 to 0.25 mL/s. Urgent indications for initiation of dialysis include uremic pericarditis, encephalopathy, and pulmonary edema due to fluid overload. Uremic symptoms (nausea, vomiting, or fatigue), acidosis, and hyperkalemia not responsive to medical therapy also prompt initiation of dialysis. Patients with diabetes are usually more symptomatic at any level of renal dysfunction compared with patients without diabetes and, hence, gen-

erally begin dialysis earlier than patients without diabetes.

The choice among the treatment modalities for ESRD depends on several factors. Transplantation is frequently the treatment of choice in infants and children with ESRD.<sup>146</sup> In contrast, patients older than 70 years have more complications with transplantation and are generally managed with hemodialysis or peritoneal dialysis. In other patients, absolute contraindications to either hemodialysis or peritoneal dialysis are few and the choice is usually based on coexistent vascular disease, patient preference, or other socioeconomic factors. With steadily improving 1- and 5-year survival rates, living related or unrelated donor transplantation is an attractive option for eligible patients.<sup>147</sup> It is important to emphasize that referral and evaluation for renal transplantation should be accomplished well in advance of the need for dialysis. With careful planning among the primary care physician, the nephrologist, and the transplant surgeon, transplantation can sometimes be performed before dialysis is required.

Accepted for publication March 23, 1998.

Reprints: Michael C. Smith, MD, Division of Nephrology, University Hospitals of Cleveland, 11100 Euclid Ave, Cleveland, OH 44106-5048.

## REFERENCES

- US Renal Data System. *USRDS 1996 Annual Data Report*. Bethesda, Md: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1996.
- Levey AS. Measurement of renal function in chronic renal disease. *Kidney Int*. 1990;38:167-184.
- Shemesh O, Goldbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. *Kidney Int*. 1985;28:830-838.
- Mitch WE, Walser M, Buffington GA, Lemann J. A simple method for estimating progression of chronic renal failure. *Lancet*. 1976;2:1326-1328.
- Shah BV, Levey AS. Spontaneous changes in the rate of decline in reciprocal serum creatinine: errors in predicting the progression of renal disease from extrapolation of the slope. *J Am Soc Nephrol*. 1992;2:1186-1191.
- Dubb JW, Stote RM, Familial RG, Lee K, Alexander F. Effect of cimetidine on renal function in normal man. *Clin Pharmacol Ther*. 1978;24:76-83.
- Berglund F, Killander J, Pompeius R. Effect of trimethoprim-sulfamethoxazole on the renal excretion of creatinine of man. *J Urol*. 1975;114:802-808.
- Schwartz WB, Kassirer JP. Medical management of chronic renal failure. *Am J Med*. 1968;44:786-801.
- Murray T, Goldberg M. Chronic interstitial nephritis: etiologic factors. *Ann Intern Med*. 1975;82:453-459.
- Kasinath BS, Mujais SK, Spargo BH, Kate AI. Non-diabetic renal disease in patients with diabetes mellitus. *Am J Med*. 1983;75:613-623.
- Parving HH, Gall MA, Skott P, et al. Prevalence and causes of albuminuria in noninsulin dependent diabetic patients. *Kidney Int*. 1992;41:758-762.
- Chihara J, Takebayashi S, Taguchi T, Yokoyama K, Harada T, Naito S. Glomerulonephritis in diabetic patients and its effect on the prognosis. *Nephron*. 1986;43:45-49.
- Analgesics and the kidney: summary and recommendations to the scientific advisory board of the National Kidney Foundation from an ad hoc committee of the NKF. *Am J Kidney Dis*. 1996;27:162-165.
- Freedman BI, Iskander S, Appel RG. The link between hypertension and nephrosclerosis. *Am J Kidney Dis*. 1995;25:207-221.
- Rostand GS, Brown G, Kirk KA, Rutzky EA, Dustan HP. Renal insufficiency in treated hypertension. *N Engl J Med*. 1996;320:684-688.
- Walker WG. Hypertension related renal injury: a major contributor to end stage renal disease. *Am J Kidney Dis*. 1993;22:164-173.
- Fogo A, Breyer JA, Smith MC, et al. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease Trial. *Kidney Int*. 1997;51:244-252.
- Appel RG, Bleyer M, Reasis S, Hansen KJ. Renovascular disease in older patients beginning renal replacement therapy. *Kidney Int*. 1995;48:171-176.
- Almeida JB, Saragoca MA, Tavares A, Cezaresi ML, Draibe SA, Ramos OL. Severe hypertension induces disturbances of renal autoregulation. *Hypertension*. 1992;19:11279-11283.
- Parving HH, Kasstrup H, Smidt UM, Anderson AD, Feldt-Rasmussen B, Sandah-Christiansen J. Impaired autoregulation of GFR in type 1 (insulin dependent) patient with nephropathy. *Diabetologia*. 1984;27:547-552.
- Brown SA, Finco DR, Navar LG. Impaired renal autoregulatory ability in dogs with reduced renal mass. *J Am Soc Nephrol*. 1995;5:1768-1774.
- Danovitch GM, Bourgoignie J, Bricker NS. Reversibility of the salt losing tendency of chronic renal failure. *N Engl J Med*. 1977;296:14-19.
- Cody RI, Ljungman S, Corit AB. Regulation of glomerular filtration rate in chronic congestive heart failure patients. *Kidney Int*. 1988;34:361-367.
- Oster JR, Materson BI. Renal and electrolyte complications of congestive heart failure and effects of therapy with angiotensin converting enzyme inhibitors. *Arch Intern Med*. 1992;152:704-710.
- Rose BD. Diuretics. *Kidney Int*. 1991;39:336-352.
- Wilson JR, Reichek N, Dunkman WB, Goldberg S. Effect of diuresis on the performance of the failing left ventricle in man. *Am J Med*. 1981;70:234-239.
- Packer M, Lee WH, Medina V, Yushak M. Influence of renal function on the hemodynamic and clinical response to long term captopril therapy in severe chronic heart failure. *Ann Intern Med*. 1986;104:147-154.
- Toto RD, Mitchell HC, Milam C, Pettinger WA. Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. *Ann Intern Med*. 1991;115:513-519.
- Papadakis MA, Wexman MP, Fraser C, Sedlacek SM. Hyperkalemia complicating digoxin toxicity in a patient with renal failure. *Am J Kidney Dis*. 1985;5:64-66.

30. Rimmer JM, Horn JF, Gennari FJ. Hyperkalemia as a complication of drug therapy. *Arch Intern Med.* 1987;147:867-869.
31. Turka LA. Urinary tract obstruction. In: Rose BD, ed. *Pathophysiology of Renal Disease.* New York, NY: McGraw-Hill Book Co; 1987:447-468.
32. Klahr S. Pathophysiology of obstructive nephropathy. *Kidney Int.* 1983;23:414-426.
33. Finberg M, Hillman B, Smith EH. Ultrasound in the evaluation of the nonfunctioning kidney. In: Rosenfield AT, ed. *Genitourinary Ultrasonography.* New York, NY: Churchill Livingstone Inc; 1979:105.
34. Kincaid-Smith P, McMichael J, Murphy EA. The clinical course and pathology of hypertension with papilledema. *QJM.* 1958;27:117-154.
35. Mitchell HC, Graham RM, Pettinger WA. Renal function during long term treatment of hypertension with minoxidil: comparison of benign and malignant hypertension. *Ann Intern Med.* 1980;93:676-681.
36. Luft FC, Block R, Szwed JJ, Grim CM, Grim CE. Minoxidil treatment of malignant hypertension. *JAMA.* 1978;240:1985-1987.
37. Humes D. Aminoglycoside nephrotoxicity. *Kidney Int.* 1988;3:900-911.
38. Appel GB. Aminoglycoside nephrotoxicity. *Am J Med.* 1990;88:35-165.
39. Smith CR, Moore RD, Lietman PS. Risk factors for aminoglycoside nephrotoxicity. *Am J Kidney Dis.* 1986;8:308-313.
40. Prins JM, Buller HRK, Tange RA, Speelman P. Once versus thrice daily gentamicin in patients with serious infections. *Lancet.* 1993;341:335-339.
41. Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. *Kidney Int.* 1993;44:643-653.
42. Blackshear JL, Davidman M, Stillman MT. Identification of risk for renal insufficiency from nonsteroidal anti-inflammatory drugs. *Arch Intern Med.* 1983;143:1130-1134.
43. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. *J Clin Pharmacol.* 1991;31:588-598.
44. Bunning RD, Barth WF, Sulindac: a potentially renal-sparing nonsteroidal anti-inflammatory drug. *JAMA.* 1982;248:2864-2867.
45. Whelton A, Stout RL, Spilman PS, Kiassan DK. Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure: a prospective, randomized, crossover comparison. *Ann Intern Med.* 1990;112:568-576.
46. Weisberg LS, Kurnik PB, Kurnik BRC. Risk of radio contrast nephropathy in patients with and without diabetes mellitus. *Kidney Int.* 1994;45:259-265.
47. Parfrey PS, Griffiths SM, Barrett BJ, et al. Contrast material induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. *N Engl J Med.* 1989;320:143-153.
48. Weinrauch LA, Haely RW, Leland OS, et al. Coronary angiography and acute renal failure in diabetic azotemic nephropathy. *Ann Intern Med.* 1977;86:55-59.
49. van Zee BE, Hoy WE, Talley TE, Jaenike JR. Renal injury associated with intravenous pyelography in nondiabetic and diabetic patients. *Ann Intern Med.* 1978;89:51-54.
50. D'Elia JA, Gleason RE, Alday M, et al. Nephrotoxicity from angiographic contrast material: a prospective study. *Am J Med.* 1982;72:719-724.
51. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and non ionic contrast media in 1196 patients: a randomized trial. *Kidney Int.* 1995;47:254-261.
52. Solomon R, Werner C, Mann D, D'Elia JA, Silva P. Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radio contrast agents. *N Engl J Med.* 1994;331:1416-1420.
53. Jacobson HR. Ischemic renal disease: an overlooked clinical entity? *Kidney Int.* 1988;34:729-743.
54. Rimmer JM, Gennari FJ. Atherosclerotic renovascular disease and progressive renal failure. *Ann Intern Med.* 1993;118:712-719.
55. Hricik DE, Dunn MJ. Angiotensin converting enzyme inhibitor induced renal failure: causes consequences and diagnostic uses. *J Am Soc Nephrol.* 1990;1:845-858.
56. Messina LM, Zelenock GB, Yao KA, Stanley JC. Renal revascularization for recurrent pulmonary edema in patients with poor controlled hypertension and renal insufficiency: a distinct subgroup of patients with arteriosclerotic renal artery occlusive disease. *J Vasc Surg.* 1992;15:73-82.
57. Pickering TG, Herman L, Devereux RB, et al. Recurrent pulmonary oedema in hypertension due to bilateral renal artery stenosis: treatment by angioplasty or surgical revascularization. *Lancet.* 1988;2:551-552.
58. Dean RH, Kieffer RW, Smith BM, et al. Renovascular hypertension: anatomic and renal function changes during drug therapy. *Arch Surg.* 1981;116:1408-1415.
59. Schreiber MI, Pohl MA, Novick M. The natural history of atherosclerotic and fibrous renal artery disease. *Urol Clin North Am.* 1984;11:327-331.
60. Strandness DE. Natural history of renal artery stenosis. *Am J Kidney Dis.* 1994;24:630-635.
61. Schreiber MJ, Pohl MA, Novick M. Preserving renal function by revascularization. *Annu Rev Med.* 1990;41:423-429.
62. Ying CY, Tiff CP, Gavras H, Chobanian AV. Renal revascularization in the azotemic hypertensive patient resistant to therapy. *N Engl J Med.* 1984;311:1070-1075.
63. Brenner BM, Mayer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation and intrinsic renal disease. *N Engl J Med.* 1982;307:652-659.
64. Klahr S, Schreiner GF, Ichikawa I. The progression of renal disease. *N Engl J Med.* 1988;318:1657-1666.
65. Baldwin DS, Neugarten J. Blood pressure control and renal insufficiency. In: Mitch WE, Brenner BM, Stein JH, eds. *The Progressive Nature of Renal Disease.* New York, NY: Churchill Livingstone Inc; 1986:81-110.
66. Klahr S. The kidney in hypertension: villain and victim. *N Engl J Med.* 1989;320:731-733.
67. Klahr S, Buerkert J, Pukerson ML. Role of dietary factors in the progression of chronic renal disease. *Kidney Int.* 1983;24:579-587.
68. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development of long term complications in insulin dependent diabetes mellitus. *N Engl J Med.* 1993;329:977-986.
69. Jacobson HR, Striker GE. Report on a workshop to develop management recommendations for the prevention of progression in chronic renal disease. *Am J Kidney Dis.* 1995;25:103-106.
70. Smith MC, Dunn MJ. Hypertension in renal parenchymal disease. In: Laragh JH, Brenner BM, eds. *Hypertension: Pathophysiology, Diagnosis, and Management.* New York, NY: Raven Press; 1995:2081-2102.
71. Brazy PC, Stead WW, Fitzwilliam JF. Progression of renal insufficiency: role of blood pressure. *Kidney Int.* 1989;35:670-674.
72. Hostetter TH, Olson JL, Rennke HJ, Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. *Am J Physiol.* 1981;241:F85-F93.
73. Yoshida Y, Fogo A, Ichikawa I. Glomerular hemodynamic changes versus hypertrophy in experimental glomerular sclerosis. *Kidney Int.* 1989;35:654-660.
74. Zucchelli P, Zuccala A, Borghi M, et al. Long term comparison between captopril and nifedipine in the progression of renal insufficiency. *Kidney Int.* 1992;42:452-458.
75. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria and progression of renal disease: the Modification of Diet in Renal Disease Study. *Ann Intern Med.* 1995;123:754-762.
76. Parving HH, Smidt UM, Hommel E, et al. Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. *Am J Kidney Dis.* 1993;22:188-195.
77. Wright JT Jr, Kusek JW, Toto RD, et al. Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot study. *Control Clin Trial.* 1996;17:3S-6S.
78. Hostetter TH, Mayer TW, Rennke HJ. Chronic effects of dietary protein on renal structure and function in the rat with intact and reduced renal mass. *Kidney Int.* 1986;30:509-517.
79. Nath KA, Kren SM, Hostetter TH. Dietary protein restriction in established injury in the rat. *J Clin Invest.* 1986;78:1199-1205.
80. Locatelli F, Alberti F, Graziani G, Bucciatti G, Re-daelli B, Giangrande A. Prospective randomized multicenter trial of effect of protein restriction on progression of chronic renal insufficiency. *Lancet.* 1991;337:1299-1304.
81. Williams PS, Stevens ME, Fass G, Irons L, Bone JM. Failure of dietary protein and phosphate restriction to retard the progression of chronic renal failure: a prospective randomized controlled trial. *QJM.* 1991;81:837-855.
82. Zeller K, Whittaker E, Sullivan L, Raskin P, Jacobson HR. Effect of restricting dietary protein on the progression of renal failure in patients with insulin dependent diabetes mellitus. *N Engl J Med.* 1991;324:78-84.
83. Ihle BU, Beck GJ, Whitworth JA, Charlwood RA, Kincaid-Smith P. The effect of protein restriction on the progression of renal insufficiency. *N Engl J Med.* 1989;321:1773-1777.
84. Pedrini T, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and non diabetic renal diseases: a meta-analysis. *Ann Intern Med.* 1996;124:627-632.
85. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease: Modification of Diet in Renal Disease Study Group. *N Engl J Med.* 1994;330:877-884.
86. Ikizler TA, Greene JH, Wingard RL, Parker RA, Hakim RM. Spontaneous dietary protein intake during progression of chronic renal failure. *J Am Soc Nephrol.* 1995;6:1386-1391.
87. Krolewski AS, Warram AS, Christlieb AR, Busick EJ, Kahn CR. The changing natural history of nephropathy in type 1 diabetes. *Am J Med.* 1985;78:785-794.
88. Anderson AR, Christiansen JS, Anderson JK, Kreiner S, Deckert T. Diabetic nephropathy in type 1 insulin dependent diabetes: an epidemiologic study. *Diabetologia.* 1983;25:496-501.
89. Sirmion MD. Renal disease in noninsulin dependent diabetes mellitus. *Am J Med Sci.* 1990;300:388-395.
90. Krolewski AS, Canessa M, Warram JH, et al. Predisposition to hypertension and susceptibility to renal disease in insulin dependent diabetes mellitus. *N Engl J Med.* 1988;318:140-145.
91. Viberti GC, Keen H, Wiseman MJ. Raised arterial pressure in parents of proteinuric insulin dependent diabetics. *BMJ.* 1987;295:515-517.
92. Rudberg S, Persson B, Dahlquist G. Increased glomerular filtration rate as a predictor of diabetic nephropathy: an eight-year prospective study. *Kidney Int.* 1992;41:822-828.
93. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. *N Engl J Med.* 1984;310:356-360.
94. Reichard P, Nilsson B, Rosenquist U. The effect of long term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. *N Engl J Med.* 1993;329:304-309.

95. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. *N Engl J Med*. 1993; 329:1456-1462.
96. Kasiske BL, Roberto SN, Ma JZ, Kiao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. *Ann Intern Med*. 1993;118: 129-138.
97. Mathiesen EF, Hommel E, Giese J, Parving HH. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. *BMJ*. 1991;303:81-87.
98. Greger R, Heidland A. Action and clinical use of diuretics. In: Cameron S, Davison AM, Grunfeld JP, Kerr D, Ritz E, eds. *Oxford Textbook of Clinical Nephrology*. New York, NY: Oxford University Press Inc; 1992:197-223.
99. Fliser D, Schroter M, Neubeck M, Ritz E. Co-administration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. *Kidney Int*. 1994;46:482-488.
100. Rudy DW, Voelker JR, Greene PK, Esparza FA, Brater DC. Loop diuretics for chronic renal insufficiency: a continuous infusion is more effective than bolus therapy. *Ann Intern Med*. 1991; 115:360-366.
101. Smith MC, Dunn MJ. Hypertension associated with renal parenchymal disease. In: Schrier RW, Gottschalk CW, eds. *Diseases of the Kidney*. Boston, Mass: Little Brown & Co; 1997:1333-1365.
102. Abraham PA, Opsahl JA, Halstenson CE, Keane WE. Efficacy and renal effects of enalapril therapy for hypertensive patients with chronic renal insufficiency. *Arch Intern Med*. 1988;148:2358-2362.
103. Reams GP, Bauer JH. Effect of enalapril in subjects with hypertension associated with moderate to severe renal dysfunction. *Arch Intern Med*. 1986;146:2145-2148.
104. Donohue JF, Kelly J, Laher MS, Doyle GD. Lisinopril in the treatment of hypertensive patients with renal impairment. *Am J Med*. 1988; 85:31-34.
105. ter Wee PM, De Micheli AG, Epstein M. Effects of calcium antagonists on renal hemodynamics and progression of nondiabetic chronic renal disease. *Arch Intern Med*. 1994;154:1185-1202.
106. Converse RL, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. *N Engl J Med*. 1992;327:1912-1918.
107. Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. *Ann Intern Med*. 1997;127:337-345.
108. Porush JG. Hypertension and chronic renal failure: the use of ACE inhibitors. *Am J Kidney Dis*. 1998;31:177-184.
109. Ritz E. Are antihypertensive drugs similar in protecting the kidney? *Am J Hypertens*. 1995;8: 535-585.
110. Mackenzie HS, Brenner BM. Current strategies for retarding the progression of renal disease. *Am J Kidney Dis*. 1998;31:161-170.
111. Maki DD, Ma JZ, Louis TA, Kasiske BL. Long-term effects of antihypertensive agents on proteinuria and renal function. *Arch Intern Med*. 1995;155:1073-1080.
112. Ruggenti P, Mosconi L, Bianchi L, et al. Long-term treatment with either enalapril or nitrendipine stabilizes albuminuria and increases glomerular filtration rate in non-insulin dependent diabetic patients. *Am J Kidney Dis*. 1994;24:753-761.
113. Velussi M, Brocco E, Frigato F, et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. *Diabetes*. 1996; 45:216-222.
114. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. *N Engl J Med*. 1996;334:939-945.
115. Ihle BU, Whitworth JA, Shahinfar S, Cnaan A, Kincald-Smith PS, Becker GJ. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency. *Am J Kidney Dis*. 1996;27:489-495.
116. The GISEN Group. Randomized placebo-controlled trial of effect of rampril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. *Lancet*. 1997;349:1857-1863.
117. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. *Arch Intern Med*. 1996;156:286-289.
118. Björck S, Mulec H, Johnsen SA, Nyberg G, Aurell M. Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy. *BMJ*. 1990;300:904-907.
119. Björck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M. Beneficial effects of angiotensin-converting enzyme inhibition on renal function in patients with diabetic nephropathy. *BMJ*. 1986; 293:471-474.
120. Björck S, Mulec H, Johnsen SA, Norden G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. *BMJ*. 1992;304:339-343.
121. Schon DA, Silva P, Hayslett JP. Mechanism of potassium excretion in renal insufficiency. *Am J Physiol*. 1974;227:1323.
122. Ponce SP, Jennings AE, Madias NE, Harrington JT. Drug induced hyperkalemia. *Medicine*. 1985; 64:357-370.
123. DeFronzo RA, Sherwin RS, Dillingham M. Influence of basal insulin and glucagon secretion on potassium and sodium metabolism: studies with somatostatin in normal dogs and normal and diabetic human beings. *J Clin Invest*. 1978;61:472.
124. Hruska KA, Teitelbaum SL. Renal osteodystrophy. *N Engl J Med*. 1995;333:166-174.
125. Delmez JA, Slatopolsky E. Renal osteodystrophy: pathogenesis and treatment. *Kidney*. 1990; 22:1-8.
126. Bushinsky DA. Bone disease in moderate renal failure: cause, nature and prevention. *Annu Rev Med*. 1997;48:167-176.
127. Hamdy NAT, Kanis JA, Beneton MNC, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. *BMJ*. 1995;310:358-363.
128. Felsenfeld M. Considerations for the treatment of secondary hyperparathyroidism in renal failure. *J Am Soc Nephrol*. 1997;8:993-1004.
129. Warnock DG. Uremic acidosis. *Kidney Int*. 1988; 34:278-287.
130. Schwartz WE, Hall PWI, Hays RM, Reiman AS. On the mechanism of acidosis in chronic renal disease. *J Clin Invest*. 1959;38:39-52.
131. van Slyke DD, Linder GC, Hiller A, Leiter L, McIntosh JF. The excretion of ammonia and titratable acid in nephritis. *J Clin Invest*. 1926;2:225-239.
132. Eschbach JW, Adamson JW. Anemia of end-stage renal disease. *Kidney Int*. 1985;28:1-5.
133. Eschbach JW. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. *Kidney Int*. 1989;35:134-148.
134. Shaw AB. Haemolysis in chronic renal failure. *BMJ*. 1967;213-216.
135. Zappacosta AR, Perras ST, Bell A. Weekly subcutaneous recombinant erythropoietin corrects anemia of progressive renal failure. *Am J Med*. 1991;91:229-232.
136. Kleinman KS, Schweitzer SU, Perdue ST, Bleifer KH, Abeis RI. The use of recombinant human erythropoietin in the correction of anemia in predialysis and its effect on renal function: a double blind, placebo-controlled trial. *Am J Kidney Dis*. 1989;14:486-495.
137. Lim VS, DeGowin RL, Zavala D, et al. Recombinant human erythropoietin treatment in predialysis patients: a double blind placebo controlled trial. *Ann Intern Med*. 1989;110:108-114.
138. Fellner SF, Lang RM, Neumann A, Korcarz C, Borow KM. Cardiovascular consequences of correction of the anemia of renal failure with erythropoietin. *Kidney Int*. 1993;44:1309-1315.
139. Beusterien KM, Nissensen AR, Port FK, Kelly M, Steinwald S, Ware JE. The effects of recombinant human erythropoietin on functional health and well being in chronic dialysis patients. *J Am Soc Nephrol*. 1996;7:763-773.
140. Raine AEG, Roger SD. Effects of erythropoietin on blood pressure. *Am J Kidney Dis*. 1991;18: 76-83.
141. Aronoff GR, Abel SR. Practical guidelines for drug dosing in patients with renal impairment. In: Schrier RW, ed. *Manual of Nephrology*. Boston, Mass: Little Brown & Co; 1995:173-185.
142. Bennett WM, Aronoff GR, Golper TA. *Drug Prescribing in Renal Failure: Dosing Guidelines for Adults*. Philadelphia, Pa: American College of Physicians; 1994.
143. Owen WE, Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. *N Engl J Med*. 1993;329:1001-1006.
144. Delmez JA, Slatopolsky E. Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. *Am J Kidney Dis*. 1992;19:303-317.
145. Kopple JD, Monteon FJ, Shaib JK. Effect of energy intake on nitrogen metabolism in non dialyzed patients in chronic renal failure. *Kidney Int*. 1986;29:734-742.
146. Broyer M, Ehrlich J, Jones E, Selwood N. Five year survival of kidney transplantation in children: data from the European registry (EDTA-ERA). *Kidney Int*. 1993;43(suppl):522-525.
147. US Renal Data System. *USRDS 1997 Annual Data Report*. Bethesda, Md: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1997.